# Rusfertide

A copy of hepcidin, the hormone that rations iron. By limiting the iron available to make red blood cells, it reduces the need for blood removal (phlebotomy) in polycythemia vera.

Also called: Mimrylo, PTG-300
Source page: https://peplogue.com/peptides/rusfertide/
Reviewed: 2026-10-12. Not medical advice.

## How it works

- Where it acts: It copies hepcidin and binds ferroportin, the channel iron uses to leave cells.
- What it changes: Less iron reaches the bone marrow, so fewer red blood cells are made.
- What people notice: Fewer blood removals (phlebotomies) needed. Injection-site reactions are common.

## What the evidence shows

- **Polycythemia vera (excess red blood cells)**: Proven. In the VERIFY trial, 77% of people needed no phlebotomy between weeks 20 and 32, against 33% on placebo.

## Side effects and risks

- common: Injection-site reactions in 47% of people in the main trial.
- common: Anemia in 26%.

Who should avoid it: Use for anything other than its approved blood condition.

## How it is taken

A weekly self-injection under the skin, alongside usual treatment.

## Legal status

- United States: undefined. Mimrylo, approved August 2026.
- European Union: undefined
- Spain: undefined. No rusfertide medicine in CIMA, so it is not authorised in Spain. Whether an EU application is under review was not confirmed.
- Germany: undefined. Not verified. No German or EU authorisation confirmed, so it cannot be sold in Germany.
- France: undefined. Not verified. EU status unconfirmed and French status not checked, so nothing can be said about sale in France.
- Italy: undefined. Not verified. No EU or Italian authorisation found, but we could not search EMA lists by name. Approved in the US only.
- Netherlands: undefined. Not verified. I found no EU or Dutch authorisation or Dutch listing. Do not assume it is available here.
- United Kingdom: undefined
- Canada: undefined
- Australia: undefined

## Questions people ask

**What does rusfertide do?**

It copies hepcidin, the hormone that rations iron. By limiting the iron available to make red blood cells, it reduces the need for blood removal (phlebotomy) in polycythemia vera.

**How well does rusfertide work?**

In the VERIFY trial, 77% of people needed no phlebotomy between weeks 20 and 32, against 33% on placebo.

**What are the side effects of rusfertide?**

Injection-site reactions in 47% of people in the main trial, and anemia in 26%.

**Is rusfertide approved?**

Yes, in the US as Mimrylo since August 2026. It is a weekly self-injection given alongside usual treatment.

## Sources

- OncLive: FDA approves rusfertide for polycythemia vera (28 Aug 2026): https://www.onclive.com/view/fda-approves-rusfertide-for-polycythemia-vera